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Expect analgesic failure; pursue analgesic success
Most analgesic drugs work well but in only a small percentage of people. Andrew Moore and
colleagues argue that we need to move away from a focus on average response and seek out
what works for each patient
AndrewMoore professor1, Sheena Derry senior research officer1, Christopher Eccleston professor2,
Eija Kalso professor 3
1Pain Research and Nuffield Division of Anaesthetics, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK; 2Centre for Pain Research,
University of Bath, Bath, UK; 3Pain Clinic, Department of Anaesthesiology, Helsinki University Central Hospital, Finland
A 2003 newspaper article caused considerable grief for the
pharmaceutical industry. Entitled, “Our drugs do not work on
most patients,”1 it claimed that most drugs worked in only
30-50% of people. While that surprised journalists and the
public, it was not news to professionals, including the then editor
of the BMJ.2
Individual patient responses vary greatly, as a clinical trial of
pregabalin in fibromyalgia shows (fig 1⇓). Pain relief is not
normally distributed but usually bimodal, being either very good
(above 50%) or poor (below 15%).3-5Using averages is unhelpful
and misleading, because “average” pain relief is actually
experienced by few (if any) patients, and it tells us nothing about
how many patients will experience clinically useful pain relief.
Research is therefore moving to responder analyses—reporting
the proportion of patients achieving outcomes that patients
consider worthwhile.
In this article we examine rates of success and failure of drugs
used in treating pain. We suggest a radical rethink of achievable
analgesic effects, and explore how anticipating and recognising
analgesic failure will help improve the management of pain.
This approach is relevant to all painful conditions, but here we
use examples from acute postoperative pain, headache, and
chronic musculoskeletal and neuropathic pain.
Measuring effectiveness
Patients want large reductions in pain intensity (typically at
least 50%, ideally no worse than mild pain6), with relief from
associated problems such as sleep disturbance and depression
but without common adverse events interfering with treatment.
Those who get better (responders) do well: recent individual
patient analyses for chronic pain interventions have shown that
people who respond experience improvements in fatigue,
depression, and sleep interference,7-9 and general measures of
function and quality of life,8 9 including ability to work.10
Non-responders have none of these benefits. This message is
easy to communicate.
An important feature of responder analysis, reflecting clinical
practice, is that everyone who withdraws from a trial for any
reason is unequivocally a non-responder: if you don’t take the
tablet you don’t get pain relief. This eliminates the need to assign
efficacy results to people no longer in trials and eliminates the
considerable bias inherent in the statistical practice of imputing
missing data.11 Imputation methods may be justified in
establishing whether interventions have analgesic effects but
not when determining clinical effectiveness.
We propose that the scientific assessment of analgesia and the
clinical practice of analgesic delivery could be simplified into
three guiding principles: measure pain in individual patients,
expect analgesic drugs to fail to provide a good response in
most patients, and prepare for the next step when failure occurs.
Defining and calculating failure for pain
drugs
The table⇓ shows drug specific success and failure rates for
postoperative pain, migraine, and chronic musculoskeletal and
neuropathic conditions. Data came predominantly from
Cochrane reviews or overviews, or individual patient data
meta-analyses using sensitive trials in patients with initial pain
of moderate or severe intensity. The reviews were done to the
highest current standards,12 avoiding known risks of bias, and
with sufficient data to minimise random chance effects.13 All
reviews used a responder definition of at least 50% pain relief
or its equivalent. When possible we did not use trials that had
imputed data by carrying the last observation forward, but for
painful diabetic neuropathy and postherpetic neuralgia, these
were the only data available for most drugs.
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The size of response rates with placebo depends on the outcome
(lower placebo rates with tougher outcomes), duration (in
chronic pain trials), and pain condition studied. We therefore
calculated the maximum possible success as 100%−placebo
response and drug specific success as active response−placebo
response. The success rate was calculated as a percentage of
maximum possible response.
Confronting failure
Drug specific success rates were above 50% for only four drugs
in acute postoperative pain (paracetamol 500 mg+ibuprofen
200 mg; paracetamol 1000 mg+oxycodone 10 mg; etoricoxib
120 mg; ibuprofen 400 mg+codeine 26-60 mg) and one in
migraine (zolmitriptan 10 mg). For all other drugs and in all
other conditions, fewer than half of patients achieved at least a
50% reduction in pain intensity. In acute postoperative pain,
the failure rate was 66% with paracetamol 1000 mg and 53%
for both ibuprofen 400 mg and diclofenac 50 mg. In migraine,
failure rates were 55-71% for most interventions. Failure rates
for non-steroidal anti-inflammatory drugs were 58-72% in
ankylosing spondylitis, ≥70% in osteoarthritis, and ≥80% in
chronic low back pain. For neuropathic conditions,
antidepressants and antiepileptics had failure rates of ≥70% in
painful diabetic neuropathy and postherpetic neuralgia, and
≥87% in fibromyalgia. Data for opioids in chronic non-cancer
pain were available only for tapentadol and oxycodone in a
combined analysis of osteoarthritis and chronic low back pain
trials; tapentadol had a failure rate of 90% and oxycodone had
a failure rate of 100%, consistent with what is seen with other
analyses for conventional strong opioids.11
Reflecting on failure
The magnitude of the failure to achieve good pain relief,
especially over the longer term in chronic pain, is sobering. The
high failure rates are a consequence of using patient centred
definitions of benefit combining high level of pain relief with
tolerable adverse events, using higher standards of evidence,
and avoiding major imputation bias. These higher standards are
backed by considerable evidence supporting their validity.
Use of responder analysis changes judgments of benefit and
risk. With failure, patients without benefit should be exposed
to no risk because the drug is stopped; only effective drugs
should continue to be prescribed. With success, considerable
benefits in terms of pain relief, sleep, fatigue, depression,
function, and quality of life are balanced against rare risk of
serious harm. Average benefits have no part in these discussions.
The good news is that success is often achieved within the first
two weeks or so of treatment or not at all,14 15 and when achieved,
tends to last.
Classic clinical trials, providing almost all our evidence in
chronic pain, may underestimate efficacy. Fixed dose regimens
may exacerbate adverse events and withdrawals, resulting in
higher failure rates. An alternative approach is to allow patient
directed titration to achieve adequate pain relief with tolerable
adverse events; only those with treatment success are then
randomised blindly between continuing therapy and placebo.
Such trials, known as enriched enrolment randomised
withdrawal trials, have lower failure rates. In fibromyalgia,
titrating pregabalin to an effective dose resulted in good drug
specific pain relief lasting six months in 15% of the original
population of patients; the overall failure rate was only 85%
compared with over 90% in classic trials.16
Drug therapy is rarely the only treatment used in chronic pain,
but clinical trials designed for regulatory purposes force us into
considering single interventions. Randomised withdrawal trials
may reflect the real world more accurately and be a better test,
but with only a single example this is speculation.
Pragmatic approach
The principles of treatment should be to measure pain, expect
and recognise analgesic failure, and to react to it, pursuing
analgesic success rather than blindly accepting failure. In any
condition, the order in which analgesics should be tried is
predicated on efficacy and safety, and adjusted for individual
patient characteristics.
A pragmatic implication of high failure rates is that populations
with pain need access to a broad range of drugs to have a better
chance of success (box). The problem is the dearth of data to
help devise starting, stopping, and switching rules. Currently,
we have no good evidence from clinical trials that switching is
successful in pain; we have a single study of limited
methodological quality17 and a suggestion of differences between
closely related tricyclics.18 Switching drugs works in other
conditions, like depression, where randomised trials show that
while drugs used individually benefited fewer than half of
patients, the majority benefited when failure was followed by
another drug.19 20
Guideline developers often restrict treatment options to one or
two drugs (such as, the NICE neuropathic pain guideline21).
They consider similar drugs to operate as a class, and so select
one as the first or only option despite possibly important
differences in pharmacokinetics or drug interactions. Less
restrictive guidance, centred on patient-clinician interaction and
a large dose of clinical wisdom as well as evidence, may do
better; the NICE osteoarthritis guidance comes close.22
Regulatory authorities also need to recognise that failure is the
norm. European regulators, unlike their US counterparts, have
refused to license any drug in fibromyalgia because of
inadequate average effect size, ignoring the fact that these drugs
work well (≥50% reduction in pain intensity) in around 10% of
patients with this difficult to treat condition. New drugs are
unlikely to be much better. A change in regulatory attitude is
overdue, would be sensible, and will benefit patients.
Clinical trial design
Chronic pain conditions are complex and associated with
considerable comorbidity. Coupled with the intricacies of pain
modulation, central nervous system changes, and genetic
influences, high failure rates with single interventions are
unsurprising. The new game in town is specificity of effect for
specific targets, but with only a small percentage of patients
benefiting. Randomised withdrawal designs seem promising,23
but there are few good examples, and they are not always
accepted or understood. New designs are also important for
non-drug interventions that produce substantial benefits in few
patients, including complementary therapies.
We need to determine how best to use the interventions we have
to provide better care for more people at lower cost. Clinical
effectiveness trials could be one way forward.24 They should
inform stopping and switching rules to underpin best practice;
outlines of informative pragmatic designs are available, building
on examples from other chronic diseases.24
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Practical implications of high failure rates
• No single drug will treat successfully more than a minority of patients with a painful condition
• Successful pain relief is also likely to improve sleep, depression, fatigue, quality of life, function, and ability to work
• Experience (and some evidence) suggests that failure with one drug does not necessarily mean failure with others, even within a
class
• We do not know the best order in which to use drugs, in terms of efficacy, harm, or cost
• Success or failure can be determined within 2-4 weeks, and success, when achieved, tends to be long lasting
• Because success rates are low, a wide range of drugs is needed to do the best for most patients, especially in complex chronic
conditions
Conclusion
Embracing high failure rates is the first step to doing better with
what we have. Pronouncing about the importance of failure is
rare in science. We believe that pain medicine has now reached
a degree of maturity where it can confront its failings. We
propose a radical transformation in how we establish analgesic
efficacy and harm. Clinically this means expecting analgesic
failure, assessing pain, and understanding options for stopping
and switching. For the drug industry, regulators, and researchers
this means casting aside our slavish reliance on the average,
and asking what works for whom in what circumstance,
recognising that population improvements in overall effect will
require access to numerous treatment options to achieve pain
relief for the individual.
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Table
Table 1| Success and failure of drug treatment for acute and chronic painful conditions
Treatment specific effects (% of
maximum)Failure
(maximum−
active)
Success
(active−
placebo)
Maximum
possible
success
(100−placebo)
% with outcome
Drug and dose (mg)
FailureSuccessPlaceboActive
Acute pain (single dose postoperative)w1; outcome: ≥50% maximum pain relief over 6 hours
29712664901074Paracetamol 500+ibuprofen 200
37633255871368Paracetamol 1000+oxycodone 10
40603653891164Etoricoxib 120
44563646821864Ibuprofen 400+codeine 25.6-60
5149474693753Paracetamol 1000+codeine 60
53474338811957Diclofenac 50
53474640861454Ibuprofen 400
56444837851552Naproxen 500/550
66345428821846Paracetamol 1000
68325727841643Aspirin 1000
Acute migraine headache (single dose)w2-w5; outcome: no worse than mild pain at 2 hours
48523234663468Zolmitriptan 10
55453932712961Rizatriptan 2.5
57434332752557Ibuprofen 400
57433929683261Sumatriptan 100
69314420643656Paracetamol 1000
71294820683252Aspirin 1000
Osteoarthritis (12 weeks’ treatment)6 w6-w8; outcome: ≥50% pain intensity reduction
71294920693151Tanezumab 10
73275621772344Etoricoxib 60
73275621772344Naproxen 1000
78226117782239Celecoxib 200
80204010505060Topical diclofenac 1.5%
84166112732739Ibuprofen 2400
86146010703040Duloxetine 60/100
Ankylosing spondylitis (6 weeks’ treatment)w9; ≥50% reduction in BASDI
58425036861450Etoricoxib 120
63375432861446Etoricoxib 90
72286224861438Naproxen 1000
Chronic low back pain (12 weeks’ treatment)5 w6; outcome ≥50% pain intensity reduction
82185312653547Etoricoxib 60
82185312653547Etoricoxib 90
8713619703039Duloxetine 60/100
Painful diabetic neuropathy (12 weeks’ treatment)w10-w12; outcome ≥50% pain intensity reduction
70305222742648Duloxetine 60/100
77235416703046Pregabalin 600*
78226017772340Gabapentin ≥1200*
87136510752535Lacosamide 400*
8713629712938Pregabalin 300*
Postherpetic neuralgia (12 weeks’ treatment) w10 w11 w13; outcome ≥50% pain intensity reduction or PGIC
71296125861439Pregabalin 600*
81196114752539Topical capsaicin 8%
79217019891130Pregabalin 300*
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(continued)
Treatment specific effects (% of
maximum)Failure
(maximum−
active)
Success
(active−
placebo)
Maximum
possible
success
(100−placebo)
% with outcome
Drug and dose (mg)
FailureSuccessPlaceboActive
84166713802033Gabapentin ≥1200*
Fibromyalgia (12 weeks’ treatment6 w14; outcome ≥50% pain intensity reduction
87137211831728Duloxetine 60/100
919778851523Pregabalin 600
937796851521Pregabalin 450
955814851519Pregabalin 300
Osteoarthritis and chronic low back painw15; outcome ≥50% pain intensity reduction
91969.96.676.523.530.1Tapentadol 200-500
100079.2-2.776.523.520.8Oxycodone 40-100
BASDI=Bath Ankylosing Spondylitis Disease Activity Index; PGIC=patient global impression of change.
*Used imputation by last observation carried forward.
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Figure
Fig 1 Individual changes in pain over 14 weeks of treatment with pregabalin 450 mg in 200 patients with fibromyalgia
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